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Purpose: To evaluate the feasibility and efficacy of simultaneous integrated boost intensity-modulated radiation
therapy (SIB-IMRT) in patients with limited-disease small-cell lung cancer (LD-SCLC).
Methods: Patients with LD-SCLC were treated with SIB-IMRT within 1 week after completion of 2 cycles of induction
chemotherapy. Then 2-4 cycles of adjuvant chemotherapy were administered within 1 week after SIB-IMRT. Irradiation
was given accelerated hyper-fractionated with the prescribed dose 57Gy at 1.9Gy twice daily to the gross tumor
volume (GTV) , 51Gy at 1.7Gy twice daily to the clinical tumor volume (CTV) and 45Gy at 1.5Gy twice daily to the
planning target volume (PTV). The chemotherapy regimen consisted of platinum plus etoposide. Prophylactic cranial
radiation (25Gy in 10 fractions) was administered to patients who got complete response (CR) or near complete
response (nCR). The primary endpoint of this study was the frequency of grade 3 or higher acute non-hematologic
treatment-related toxicities. Secondary end points included objective response, overall survival (OS), progression-free
survival (PFS), locoregional recurrence-free survival (LRFS).
Results: A cohort of 35 patients were enrolled in the study, the biological equivalent dose (BED) of the GTV in the
SIB-IMRT was 59.16Gy. Grade 1, 2, and 3 esophagitis were observed in 11 (31%), 12 (34%), and 6 (17%) patients,
respectively; Grade 1 and 2 pneumonitis were observed in 8 (23%) and 4 (11%) patients, respectively. The median
OS and PFS of the whole group were 37.7 months and 29.3 months, respectively. The 1- and 2-year OS was 94.1% and
68.5%, respectively. The 1- and 2-year PFS was 76.8% and 40.7%, respectively. The 1- and 2-year LRFS was 87.7% and
73.8%, respectively.
Conclusions: SIB-IMRT was feasible and well-tolerated in patients with LD-SCLC, and worth further evaluating in a large
prospective clinical trial.
Keywords: Small-cell lung cancer, Lung neoplasms, Limited-stage, Simultaneous boost intensity-modulated
radiotherapy, Outcome assessmentIntroduction
Small cell lung cancer (SCLC) accounts for 10%-15% of all
lung cancer cases [1]. At the time of diagnosis, 30%-40%
of SCLC patients present with limited disease (LD) which
is defined as disease confined to the hemithorax and the
regional lymphatic nodes according to the Veterans Ad-
ministration Lung Study Group staging [2].* Correspondence: baoshli1963@163.com
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SCLC) with improved local control and overall survivals
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however, the optimal radiotherapy approach remains
controversial with respect to timing, dose-fractionation,
and target definition. As far as dose-fractionation is con-
cerned, accelerated hyper-fractionated radiotherapy (45Gy
with 1.5Gy twice daily in 3 weeks) and dose-escalated con-
ventional radiotherapy (60-70Gy with 2Gy once daily in 6
to 7 weeks ) have been documented as reliable schedules,
and an international randomized trial is ongoing to com-
pare these two schedules concurrent with chemotherapy
in the treatment of LD-SCLC [5].
Despite of high sensibility to chemotherapy and radio-
therapy, SCLC is characterized by inevitable local recur-
rence and distant metastasis due to its aggressive nature.
As a dose-response relationship exists in treating LD-
SCLC, it is reasonable to apply appropriately high doses
to adequate target volumes as long as increased toxic-
ities are acceptable to achieve better local control and
subsequently longer survival [6]. Komaki et al. [7] found
that high-dose thoracic radiation given twice daily dur-
ing cisplatin-etoposide (EP) chemotherapy for LD-SCLC
improved the rates of local control. Simultaneous inte-
grated boost intensity-modulated radiotherapy (SIB-
IMRT), in which different dose prescriptions can be
delivered simultaneously to different target volumes in
the same treatment fraction, has been advocated in recent
years as a dose intensification technique, in which the
overall treatment time was reduced, but boosted doses to
corresponding volumes were produced [8-11].
To investigate the feasibility and effectiveness of SIB-
IMRT as a dose intensification technique for patients with
LD-SCLC, we conducted a single-center, open-label, and
prospective phase II clinical study. The primary objectives
of the study were to determine the safety and tolerability
of SIB-IMRT in combination with chemotherapy. The
secondary objectives included response rate, local control
rate, and survival rate of SIB-IMRT in combination with
chemotherapy.Methods and materials
Eligibility criteria
The inclusion criteria included: Eastern Cooperative
Oncology Group (ECOG) performance status of 0-2
grade; life expectancy ≥ 6 months; less than 75 years; no
chemotherapy or radiotherapy prior to the study; no ser-
ious complications, such as hypertension, coronary heart
disease, and psychiatric history; hemoglobin ≥ 100 g/L;
white blood cell count ≥ 3.5 × 109/L; neutrophil count ≥
1.5 × 109; platelet count > 100 × 109/L; serum creatin-
ine ≤ 1.5 × the upper limit of normal (ULN); serum bili-
rubin ≤ 2.5 × ULN; Glutamic oxalacetic transaminase and
glutamic-pyruvic transaminase ≤ 2.5 × ULN; and alkline
phosphatase ≤ 2.5 × ULN.Exclusion criteria
The exclusion criteria were as follows: known distant
metastasis; history of carcinoma other than SCLC; other
serious diseases such as myocardial infarction in the last
6 months; participation in other clinical trials in the last
4 weeks or at present; use of other anti-cancer drugs; and
a history of organ transplantation. The study was per-
formed after obtaining patients’ consent and under proto-
cols approved by the institutional review boards of the
Shandong Cancer Prevention and Treatment Research
Ethics Committee.
Pre-treatment evaluation
Patients were required to undergo a complete medical his-
tory before enrollment in the study. To exclude distant
metastases, the pre-treatment assessment included a bone
scan and computed tomography (CT) scan of the head,
neck, chest, and abdomen. A physical examination, elec-
trocardiogram, complete blood count, urinalysis, chemis-
try tests (including liver and kidney function tests),
electrolytes, coagulation panel, and tumor markers
were also required. Disease staging was performed ac-
cording to the American Joint Committee on Cancer
(AJCC version 7.0).
Chemotherapy
The patients were treated with 2 cycles of induction
chemotherapy, followed by TRT within 1 week after com-
pletion of the second cycle of chemotherapy. Then 2-4 cy-
cles of adjuvant chemotherapy were administered within
1 week after completion of TRT. Chemotherapy consisted
of etoposide (100 mg/m2 intravenously on days 1-5) and
cisplatin (25 mg/m2 intravenously on days 1-3) and was
administered every 3 weeks.
Radiotherapy
The patients were immobilized using plastic mesh mask
in the supine position and then, consecutively underwent
four-dimensional computed tomography (4DCT) scan-
ning under free breathing conditions on a 16-slice CT
scanner (Philips Brilliance Bores CT). During the scanning
procedure, respiratory signals were recorded using the
Varian Real-Time Position Management respiratory gating
hardware. After 4DCT scanning, the 4D software read all
reconstructed images along with the respiratory phases.
Images were evenly sorted into 10 phases distributed over
a breathing cycle and all CT images were imported
into the treatment planning system (Eclipse 8.6, Varian
Medical Systems, Palo Alto, CA).
The targets were delineated according to the following
criteria. Gross tumor volume (GTV) was manually delin-
eated on all 10 phases of the 4DCT scan. The GTV re-
ferred to the restaging chest CT obtained after induction
chemotherapy, including the residual primary tumor and
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lymph nodes resolved after induction chemotherapy, the
previously involved lymph node regions were still included
in the radiation target by reviewing the pre-chemotherapy
CT scan. Elective treatment of clinically uninvolved
lymphatic regions was not carried out. The clinical
tumor volume (CTV) was defined by the expanding
GTV with a 0.5 cm margin and the planning target
volume (PTV) was defined by the expanding CTV with a
0.5 cm margin. The prescribed dose was 57Gy in 30
fractions at 1.9Gy per fraction to the GTV, 51Gy in 30
fractions at 1.7Gy per fraction to the CTV, and 45Gy in
30 fractions at 1.5Gy per fraction to the PTV.
All fractional doses were given twice daily with at least
6 h between fractions and 5 times each week. All plans
aimed to cover at least 95% of the PTV with the 90%
isodose, to have minimum dose > 90% and maximum
dose < 110%. The dose–volume histogram (DVH) con-
straints of the organs at risk (OARs) were as follows: mean
lung dose < 20Gy and lung V20 < 33%, spinal cord Dmax ≦
45Gy, mean heart dose < 30Gy and heart V40 < 46% , mean
esophagus dose < 34Gy, esophagus V35 < 50% [12,13].
The patients were treated based on a twice-daily three-
dimensional cone beam computed tomography (CBCT)
anatomy registration. CBCT images were acquired using a
scanner attached to the gantry of the Trilogy Linear Accel-
erator (Varian Medical Systems). The discrepancy between
planned and actual tumor position was automatically eval-
uated based on the automated alignment software. When
the quality of a known parameter (such as bony landmarks
in the chest) was ambiguous, the tumor contour was
manually aligned to verify the automatic alignment
results.
The biological equivalent dose (BED) was calculated using
the linear quadratic formula: BED ¼ ndð Þ 1þ d= α=βð Þ½  −
0:693t=αTpotð Þ, where n = the total number of fractions
delivered; d = the dose per fraction (Gy); α/β = 10
for acute effects and tumor control and 3 for chronic
effects; α = 0.3Gy-1; t = total days in which radiotherapy
is delivered; and Tpot = potential doubling time (5.6
days) [14].
Prophylactic cranial irradiation (PCI)
After completion of chemotherapy and TRT, patients who
achieved a complete response (CR) or near complete re-
sponse (nCR) were offered the option of PCI. Patients were
administered PCI (25Gy in 10 fractions to the entire brain)
within 4 weeks after completion of all chemotherapy.
Adverse effect assessment
Side effect assessment was graded at least weekly using
the National Cancer Institute Common Toxicity Criteria
(version 3.0) during radiotherapy and chemotherapy
period. 3 months after the treatment, late toxicities wereevaluated according to the Radiation Therapy Oncology
Group (RTOG)/European Organization for Research and
Treatment of Cancer late radiation morbidity scoring
schema.Follow-up
The treatment response was estimated using CT or posi-
tron emission tomography/computed tomography after
treatment, according to the Response Evaluation Criteria
in Solid Tumors (version 1.0). Follow-up after treatment
completion was every 3 months over the first 2 years and
every 6 months thereafter. Each visit included medical
history, physical examination, complete blood count, chest
and abdomen CT, brain magnetic resonance imaging/CT,
and bone scan (if necessary).Study endpoints and statistics
The primary endpoint of this study was the frequency of
grade 3 or higher acute non-hematologic treatment-
related toxicities. Secondary end points included objective
response, overall survival (OS), progression-free survival
(PFS), locoregional recurrence-free survival (LRFS). OS
was observed from the first day of treatment until death
or last follow-up time, PFS was observed from the first
day of treatment until progress, death or last follow-up
time, and LRFS was observed from the first day of treat-
ment until recurrence, death or last follow-up time. The
Kaplan–Meier method was used to estimate OS, PFS and
LRFS using SPSS® v. 17.0 (SPSS Inc, Chicago, IL).Results
Patient characteristics
Between AUG, 2009 and FEB, 2013, 44 SCLC patients in
Shandong Cancer Hospital & Institute were enrolled in
the study. 9 patients were excluded from the analysis of
eligible patients, and leaving 35 assessable patients. The
reasons for ineligibility were extensive disease (3), incom-
plete staging studies (1), absence of study data (2) and lose
of follow up (3). All of the 35 patients finished the planned
induction chemotherapy, radiotherapy, and adjuvant
chemotherapy. 22 patients were given PCI within
4 weeks after completion of all chemotherapy. Of the
35 patients, 14 patients had stage IIIA, 15 had stage IIIB,4
had stage IIA, 1 had stage IIB, and 1 had stage IA. The
median age was 54 years (range, 35-72 years). The patients’
characteristics were summarized in Table 1.Radiotherapy plan evaluation
The BED of the GTV in the SIB-IMRT was 59.16Gy. The
evaluation of the DVH-based parameters of the OARs
were shown in Table 2.
Table 1 Characteristics of 35 patients
Characteristic Number of cases (%)


















Abbreviations: ECOG Eastern Cooperative Oncology Group.
AJCC American Joint Committee on Cancer, T Tumor, N Node.




MLD (Gy)a 14.8 ± 1.7
V5 (%)b 67.4 ± 9.0
V10 (%)b 53.5 ± 7.2
V20 (%)b 28.7 ± 3.2
V30 (%)b 17.1 ± 2.6
Ipsilateral lungs
MLD (Gy) 22.1 ± 4.1
V5 (%) 79.1 ± 10.7
V10 (%) 70.7 ± 11.8
V20 (%) 47.2 ± 11.3
V30 (%) 30.3 ± 10.0
Contralateral lungs
MLD (Gy) 8.8 ± 2.9
V5 (%) 53.1 ± 13.1
V10 (%) 32.1 ± 12.7
V20 (%) 11.8 ± 8.8
V30 (%) 5.2 ± 4.6
Spinal cord
Dmax (Gy)e 42.7 ± 3.7
Heart
Dmean (Gy)a 16.1 ± 7.3
V30 (%)c 23.3 ± 15.0
V40 (%)c 9.0 ± 5.0
Esophagus
MED (Gy)a 29.0 ± 6.7
V45 (%)d 33.6 ± 5.3
Abbreviations: SD standard deviation. aThe mean irradiation dose that the lung,
heart and esophagus received, respectively; bthe volume of the lung that
received the 5, 10, 20 and 30Gy irradiation dose, respectively; cthe volume of the
heart that received 30 and 40Gy irradiation dose, respectively; dthe volume of the
esophagus that received 45Gy irradiation dose; ethe maximum irradiation dose
that spinal cord received.
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The toxicities for each patient were presented in detail
(Table 3). 15(43%)and 7(20%)patients had grade 3 and 4
hematologic toxicity, respectively. Necessary treatment
measures, such as recombinant human interleukin and
granulocyte colony stimulating factor, were provided and
blood transfusion were given to the patients with grade
4 hemoglobin toxicity (All patients fully recovered from
hematologic toxicity). Of the 35 patients, grade 1, 2, and 3
esophagitis occurred in 11 (31%), 12 (34%), and 6 (17%)
patients, respectively; the patients with grade 3 esophagitis
required intravenous nutrition. Grade 1 and 2 pneumon-
itis occurred in 8 (23%) and 4 (11%) patients, respectively.
None of the patients died of treatment-related causes.Treatment response
The efficacy of induction chemotherapy was observed in
35 patients; 29 patients achieved partial response (PR), 4
patients achieved CR and 2 patients had stable disease
(SD). 4 weeks after radiotherapy and chemotherapy, of the
35 patients, 51% of patients (n = 18) had CR, 11% of
patients (n = 4) had nCR, and another 26% (n = 9) had PR,
for an overall response rate of 88%; another 9% of patients
(n = 3) had SD, 3% (n = 1) had progressive disease (PD),
and no one died before the 4 weeks post-treatment
response could be evaluated.Survival
The median follow-up was 24.6 months, with a range of
6–53.5 months until the last follow-up date (15 August
2014). The median OS and PFS of the entire group were
37.7 and 29.3 months, respectively. The OS, PFS and
LRFS were illustrated in Figures 1, 2, and 3, respectively.
The 1- and 2-year OS were 94.1% and 68.5%, respectively.
The 1- and 2-year PFS were 76.8% and 40.7%, respectively.
The 1- and 2-year LRFS were 87.7% and 73.8%, respect-
ively. At the last follow-up, 15 (43%) patients were alive
with no evidence of failure. Local regional recurrences
only developed in 4 (11%) patients and distant metastases
only occurred in 12 (34%) patients. 4 (11%) patients had a
Table 3 Treatment-related toxicity
Grade (n = 35) number (percent)
of patients
Category 1 2 3 4
Hematologic toxicity (WBC) 4(11%) 21(60%) 9(26%) 1(3%)
Hematologic toxicity (PLT) 4(11%) 2(6%) 2(6%) 3(9%)
Hematologic toxicity (HB) 8(23%) 5(14%) 4(11%) 3(9%)
Stomach/intestine 13(37%) 11(31%) 2(6%) 0
Esophagitis 11(31%) 12(34%) 6(17%) 0
Pneumonitis 8(23%) 4(11%) 0 0
Weight loss 3(9%) 1(3%) 0 0
Skin (within the irradiated field) 2(6%) 0 0 0
Fever 1(3%) 3(9%) 0 0
Abbreviations: WBC white blood cell, PLT platelet, HB hemoglobin.
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Among the 16 patients who developed distant metastases,
the most common sites were brain (n = 6), followed by
liver (n = 3), adrenals (n = 2), lung (n = 2), bone (n = 1),
subcutaneous tissue (n = 1) and supraclavicular lymph
nodes (n = 1).
Discussion
The best method of integrating thoracic radiation with
chemotherapy includes conflicting reports. Turrisi et al.
[15] conducted a randomized trial that demonstrated a
twice daily regimen of 45Gy/30 fractions over 3 weeks
that produced an acute grade 3 esophagitis rate of 27%,
a local regional failure rate of 36%, and a 2-year OS rateFigure 1 Kaplan–Meier plot of overall survival.of 47% was superior to 45Gy in 25 daily fractions. The
NCCTG 95-20-53 trial [16], which included 6 cycles of EP
and cycles 4 and 5 included concurrent chemotherapy
and TRT (30Gy/20 twice daily fractions, a 2-week break,
and another 30Gy/20 twice daily fractions), resulted in a
favorable 5-year survival rate of 24%; however, the locore-
gional failure remained a problem and grade 3 or grade
3+ toxicity were as high as 97%. In the RTOG 0239 study
[7], patients with LD-SCLC were given thoracic radiation
to 61.2Gy over 5 weeks (daily 1.8Gy fractions on days 1-
22, then twice daily 1.8Gy fractions on days 23-33), and
the rate of grade 3 esophagitis was 18% and local regional
failure rate was 20%, but the 2-year OS rate of 36.6% did
not reach the projected goal. A newer method should
allow the safe administration of higher doses of TRT.
In the present study, we first applied SIB-IMRT that
delivered GTV at 57Gy in 30 fractions, CTV at 51Gy in
30 fractions, and PTV at 45Gy in 30 fractions twice daily
over 3 weeks. The dose could be escalated in a single plan
for the entire treatment, but still met dose constraints to
critical normal structures, such as the heart, lung, esopha-
gus, and spinal cord. Favorable results were achieved, with
grade 3 esophagitis rate of 17%, and 2-year OS of 68.5%,
and 2-year LRFS was 73.8%. Of note, the sample size of
the study was small.
Despite concurrent chemoradiotherapy represents the
standard treatment for patients with LD-SCLC, we applied
sequential chemoradiotherapy in the current trial consid-
ering serious toxicity from concurrent chemoradiotherapy
and insufficient supportive treatment in developing
country [17]; meanwhile, we supposed that sequential
Figure 2 Kaplan–Meier plot of progression-free survival.
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moradiotherapy. SCLC is characterized by the predomin-
antly central type and bulky tumor [1], so hematologic
toxicity and esophagitis are more severe in the concurrent
regimen. Choi et al. [18] reported that esophagitis limited
treatment when total dose from twice daily treatment
exceeded 45Gy concurrent chemotherapy. Furthermore, in
a phase III study from the Japanese Clinical Oncology
Group , 231 patients who received 4 cycles of cisplatin plus
etoposide were randomly assigned to either sequential orFigure 3 Kaplan–Meier plot of locoregional recurrence-free survival.concurrent twice daily 45Gy TRT. There was no statisti-
cally significant difference (p = 0.097) in survival between
the two groups [19].
Our results in the 35 patients treated according to the
upper approach indicate clear feasibility. The main toxicity
problems of our study were grade 3 esophagitis and grade
2 pneumonitis, affecting 17% and 11%, respectively. The
17% severe acute esophagitis rate in this study was higher
than the 4% experienced in the sequential arm of Japanese
Clinical Oncology Group Study 9104 because of the
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not lead to limitation, and all the affected patients recov-
ered their ability to swallow. The grade 3 esophagitis rate
was lower than the 27% occurred in the twice daily arm of
INT 0096. The INT 0096 protocol called for starting thor-
acic radiation on day 1 of chemotherapy on the basis of
other studies showing that local control and survival were
better when the radiation was started early relative to the
chemotherapy [20,21]. The TRT in this study began within
1 week after completion of the 2nd cycle of chemotherapy,
which may allow us to reduce the volume of esophagus
within the radiation fields and synergetic toxicity during
therapy.
Thoracic RT affects the patient outcome by decreasing
the tumor burden within the chest, resulting in enhanced
local control and survival [3,4]. Despite the addition of
thoracic RT to chemotherapy, local treatment failures
occur in approximately one third of patients treated
with the currently accepted optimal therapy in LD-SCLC
[16]. Recent evidence supports the hypothesis that TRT
dose intensification improves LD-SCLC patients’ out-
comes [6]. Our results supported this view and showed
a favourable outcome that the 2-year LRFS was 73.8%,
which was in agreement with the data reported by
RTOGP0239 [7].
As a dose-response relationship exists in treating LD-
SCLC, local control and subsequent survival are associ-
ated with dose-fractionation parameters [13]. The 2-year
OS rate of 68.5% in the present study was higher than
the 47% in the twice-daily arm of INT 0096 and the
36.6% in the RTOGP0239. Compared to the INT 0096,
we got a higher BED of 59.16Gy to the tumor with the
SIB-IMRT. The BED can be used to compare the effi-
cacy of various dose-fractionation regimens in providing
tumor control and survival [22,23].
Distant metastasis was the dominant cause of failure
and the most common site was brain (17%) in present
study. Several meta-analyses and randomized trials have
focused on the role of PCI in patients with SCLC. A meta-
analysis [24] involving 987 patients with SCLC and a CR
to chemotherapy showed a 5.4% increase in the 3-year
survival for those undergoing PCI. Although Tai et al. [25]
reported that patients with a PR benefited from PCI, with
a reduced rate and delayed time for development of brain
metastases, patients who got CR or nCR were given PCI
in this study. 22 patients were given PCI and there were
10 patients in whom disease progressed after PCI (3 [14%]
with brain metastases), which was higher than Tai et al.
reported (9%).
In conclusion, the regimen was safe and well-tolerated,
and demonstrated an encouraging outcome in patients
with LD-SCLC. But this study based on small sample
size and further randomized studies should be carried
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